3,5-二(三氟甲基)苄基甲烷磺酸酯 | 183551-51-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,5-二(三氟甲基)苄基甲烷磺酸酯
• 英文名称: 3,5-bis(trifluoromethyl)benzyl methanesulfonate
• 英文别名: 3,5-bis-(trifluoromethyl)benzyl mesylate；[3,5-Bis(trifluoromethyl)phenyl]methyl methanesulfonate
• CAS: 183551-51-1
• 化学式: C₁₀H₈F₆O₃S
• 分子量: 322.228
• InChiKey: ZPWKYNJFFAWNSM-UHFFFAOYSA-N

物化性质

• 熔点：
  61-62 °C(Solv: ethyl acetate (141-78-6); isopropyl ether (108-20-3))
• 沸点：
  303.0±42.0 °C(Predicted)
• 密度：
  1.487±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  9

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2906299090
• 安全说明：
  S26

反应信息

• 作为反应物：
  描述：

  3,5-二(三氟甲基)苄基甲烷磺酸酯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 N-[3,5-bis(trifluoromethyl)benzyl]-2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-5-methyl-4-phenylnicotinamide
  参考文献：
  名称：

  Amide-based atropisomers in tachykinin NK1-receptor antagonists: synthesis and antagonistic activity of axially chiral N-benzylcarboxamide derivatives of 2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocin-6-one

  摘要：

  A series of novel N-benzylcarboxamide derivatives of bicyclic compounds, 3,4-dihydropyrido[3,2-f][1,4]oxazepin-5(2H)-one and 2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocin-6-one, were synthesized by cyclization of N-benzyl-2-chloro-N-(2-hydroxyethyl)-and -(3-hydroxypropyl)-nicotinamides, respectively. Atropisomerism was observed in 5-[3,5-bis(trifluoromethyl)benzyl]-7-phenyl-2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocin-6-ones due to steric hindrance of the carboxamide moiety and restriction of its rotation. Cyclization of N-[3,5-bis(trifluoromethyl)benzyl]-2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-5-methyl-4-phenylnicotinamide gave (3S)5-[3,5-bis(trifluoromethyl)benzyl]-3,8-dimethyl-7-phenyl-2,3,4,5-tetrahydro-6H-pyrido[2,3b][1,5]oxazocin-6-one, which exists predominantly in the thermodynamically stable aR-conformer in CDCl3. This compound showed excellent NK1-antagonistic activity with IC50 value (in vitro inhibition of [I-125]-Bolton-Hunter-substance P binding in human IM-9 cells) of 0.47 nM, which is ca. 200-fold more potent than that of its enantiomer, indicating that the atropisomer chirality affects NK1-receptor recognition. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2004.01.097
• 作为产物：
  描述：

  3,5-双三氟甲基苄醇 、 甲基磺酰氯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以95%的产率得到3,5-二(三氟甲基)苄基甲烷磺酸酯
  参考文献：
  名称：

  Amide-based atropisomers in tachykinin NK1-receptor antagonists: synthesis and antagonistic activity of axially chiral N-benzylcarboxamide derivatives of 2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocin-6-one

  摘要：

  A series of novel N-benzylcarboxamide derivatives of bicyclic compounds, 3,4-dihydropyrido[3,2-f][1,4]oxazepin-5(2H)-one and 2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocin-6-one, were synthesized by cyclization of N-benzyl-2-chloro-N-(2-hydroxyethyl)-and -(3-hydroxypropyl)-nicotinamides, respectively. Atropisomerism was observed in 5-[3,5-bis(trifluoromethyl)benzyl]-7-phenyl-2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocin-6-ones due to steric hindrance of the carboxamide moiety and restriction of its rotation. Cyclization of N-[3,5-bis(trifluoromethyl)benzyl]-2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-5-methyl-4-phenylnicotinamide gave (3S)5-[3,5-bis(trifluoromethyl)benzyl]-3,8-dimethyl-7-phenyl-2,3,4,5-tetrahydro-6H-pyrido[2,3b][1,5]oxazocin-6-one, which exists predominantly in the thermodynamically stable aR-conformer in CDCl3. This compound showed excellent NK1-antagonistic activity with IC50 value (in vitro inhibition of [I-125]-Bolton-Hunter-substance P binding in human IM-9 cells) of 0.47 nM, which is ca. 200-fold more potent than that of its enantiomer, indicating that the atropisomer chirality affects NK1-receptor recognition. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2004.01.097

文献信息

• Synthesis of Isoxazolines from Nitroalkanes <i>via</i> a [4+1]‐Annulation Strategy
  作者：Pavel Yu. Ushakov、Elizaveta A. Khatuntseva、Yulia V. Nelyubina、Andrey A. Tabolin、Sema L. Ioffe、Alexey Yu. Sukhorukov

  DOI：10.1002/adsc.201901000

  日期：2019.12.3

  using the [4+1]‐annulation of α‐keto‐stabilized sulfur ylides with N,N‐bis(siloxy)enamines derived from aliphatic nitro compounds. The resulting 5‐keto‐substituted isoxazolines were shown to be convenient precursors of polysubstituted 3‐hydroxypyrrolidines via the one‐pot catalytic N−O hydrogenolysis/intramolecular reductive amination sequence. Application of this approach to the formal synthesis of Merck's

  利用由脂肪族硝基化合物衍生的N，N-双（甲硅烷氧基）烯胺与α-酮稳定的硫基化合物的[4 + 1]-环化反应，开发了一种新型的异恶唑啉通道。通过一锅催化的N-O氢解/分子内还原胺化序列显示，所得的5-酮基取代的异恶唑啉是多取代的3-羟基吡咯烷的便​​利前体。证明了该方法在默克强力NK 1受体拮抗剂正式合成中的应用。
• Cyclic compounds, their prudiction and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05770590A1

  公开（公告）日：1998-06-23

  Novel compounds of the following general formula or salts thereof. ##STR1## wherein Ring M is a heterocyclic ring having --N.dbd.C<, --CO--N< or --CS--N< as the partial structure --X . . . Y<; R.sup.a and R.sup.b are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, and at least one of them is optionally substituted heterocyclic ring; Rng C is optionally substituted homocyclic or heterocyclic ring; Rng Z is an optionally substituted ring; and n represents an integer of from 1 to 6, or a salt thereof, which has anexcellent tachykinin receptor antagonistic effect, and their production, and pharmaceutical compositions.

  具有以下通式的新化合物或其盐：##STR1##其中，环M是一个具有--N.dbd.C<、--CO--N<或--CS--N<作为部分结构--X . . . Y<的杂环环；R.sup.a和R.sup.b相互连接形成环A，或者它们相同或不同，独立地代表氢原子或环M上的取代基；环A和环B独立地代表可选择性取代的碳环或杂环，其中至少有一个是可选择性取代的杂环；环C是可选择性取代的碳环或杂环；环Z是可选择性取代的环；n代表1至6的整数，或其盐，具有优异的速激肽受体拮抗作用，以及它们的制备方法和药物组合物。
• Heterocyclic compounds, their production and use
  申请人：——

  公开号：US20020132817A1

  公开（公告）日：2002-09-19

  A compound represented by the formula: 1 wherein ring M is a heterocyclic ring wherein —X═Y< is one of —N═C<, —CO—N< or —CS—N<; R a and R b are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, with the proviso that at least one of them is an optionally substituted heterocyclic ring; Ring C is an optionally substituted homocyclic or heterocyclic ring; Ring Z is an optionally substituted nitrogen-containing heterocyclic ring; and n is an integer from 1 to 6, or a salt thereof has a tachykinin receptor antagonistic activity in vitro, and is useful for preventing or treating depression, anxiety, manic-depressive illness or psychopathy.

  一种由以下通式表示的化合物：1，其中环M为杂环环，其中—X═Y<为—N═C<、—CO—N<或—CS—N<之一；Ra和Rb彼此连接形成环A，或者它们相同或不同，独立地表示氢原子或环M上的取代基；环A和环B独立地表示可任选取代的碳环或杂环环，条件是至少一个为可任选取代的杂环环；环C为可任选取代的碳环或杂环环；环Z为可任选取代的含氮杂环环；n为1至6的整数，或其盐在体外具有速激肽受体拮抗活性，并可用于预防或治疗抑郁症、焦虑症、双相情感障碍或精神病。
• Receptor agonists
  申请人：Itoh Fumio

  公开号：US20060199795A1

  公开（公告）日：2006-09-07

  The present invention provides a TGR5 receptor agonist comprising a fused ring compound represented by the formula wherein ring A is an optionally substituted aromatic ring; and ring B′ is a 5- to 8-membered ring having one or more substituents or a salt thereof or a prodrug thereof, which is useful for the treatment of various diseases.

  本发明提供了一种TGR5受体激动剂，包括由下式表示的融合环化合物：其中环A是可选取代的芳香环；环B'是具有一种或多种取代基的5-至8-成员环，或其盐或前药，用于治疗各种疾病。
• Cyclic compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05786352A1

  公开（公告）日：1998-07-28

  Novel compounds of the following general formula or salts thereof. ##STR1## wherein Ring M is a heterocyclic ring having --N.dbd.C<, --CO--N< or --CS--N< as the partial structure --X . . . Y<; R.sup.a and R.sup.b are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, and at least one of them is optionally substituted heterocyclic ring; Ring C is optionally substituted homocyclic or heterocyclic ring; Ring Z is an optionally substituted ring; and n represents an integer of from 1 to 6, or a salt thereof, which has an excellent tachykinin receptor antagonistic effect, and their production, and pharmaceutical compositions.

  以下是通用式或其盐的新化合物。其中环M是具有-N=C-, -CO-N或-CS-N的部分结构--X...Y的杂环，R.sup.a和R.sup.b相互结合形成环A，或者它们相同或不同且分别独立地表示环M上的氢原子或取代基；环A和环B分别表示可选取代的同环或异环，其中至少一个是可选取代的异环；环C是可选取代的同环或异环；环Z是可选取代的环；n表示1至6的整数，或其盐，具有优异的Tachykinin受体拮抗作用，以及它们的制备和制药组合物。